Hepatitis C Virus Clinical Trials

2 recruiting

Hepatitis C Virus Trials at a Glance

14 actively recruiting trials for hepatitis c virus are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Adana, Agra, and Alexandroupoli. Lead sponsors running hepatitis c virus studies include Asociación Colombiana de Hepatología, Atea Pharmaceuticals, Inc., and AbbVie.

Browse hepatitis c virus trials by phase

Treatments under study

About Hepatitis C Virus Clinical Trials

Looking for clinical trials for Hepatitis C Virus? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatitis C Virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatitis C Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Hepatitis C Virus (HCV)
AbbVie2,000 enrolled2 locationsNCT07419347
Recruiting
Phase 3

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Hepatitis CHepatitis C, ChronicHepatitis C Virus Infection+1 more
Atea Pharmaceuticals, Inc.880 enrolled106 locationsNCT07037277
Recruiting
Not Applicable

California MEPS Hub

Substance Use Disorder (SUD)HIV PreventionHepatitis C Virus (HCV)+3 more
University of California, Los Angeles318 enrolled3 locationsNCT07433985
Recruiting
Not Applicable

Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).

HEPATITIS C VIRUS CHRONIC INFECTIONLiver Disease Chronic
University of Guadalajara26 enrolled2 locationsNCT07487623
Recruiting
Not Applicable

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

HIVHepatitis C Virus (HCV)
McGill University Health Centre/Research Institute of the McGill University Health Centre548 enrolled9 locationsNCT07122219
Recruiting
Not Applicable

Hepatitis C Tracker Study

Hepatitis C Virus Infection
University of Southern California124 enrolled2 locationsNCT06870019
Recruiting

Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada

HCVHEPATITIS C VIRUS CHRONIC INFECTION
McGill University300 enrolled12 locationsNCT07095192
Recruiting

Early Detection of HCV in Injection Drug Users

Hepatitis C Virus Infection
Institute of Health Information and Statistics of the Czech Republic3,000 enrolled18 locationsNCT06431945
Recruiting
Not Applicable

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

Colorectal Cancer ScreeningHepatitis C Virus
H. Lee Moffitt Cancer Center and Research Institute350 enrolled1 locationNCT06745895
Recruiting

Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development

Hepatitis C Virus Infection
Centro di Riferimento Oncologico - Aviano1,000 enrolled4 locationsNCT06718530
Recruiting

Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia

Hepatitis C Virus Infection
Asociación Colombiana de Hepatología205 enrolled1 locationNCT06463912
Recruiting

Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia

Hepatitis C Virus Infection
Asociación Colombiana de Hepatología25,669 enrolled2 locationsNCT06155006
Recruiting

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures

Hepatitis CTransmission, Intravenous Drug AbuserAddiction, Alcohol+2 more
University Hospital, Limoges1,500 enrolled1 locationNCT05361603
Recruiting
Phase 4

A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.

Chronic hepatitis C virus (HCV) infection.Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs).Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection.+1 more
Dr Joe Sasadeusz50 enrolled1 locationACTRN12608000400369